Lundbeck recently named former Millennium CEO Deborah Dunshire as its new CEO. During her time at Lundbeck, Ms. Dunshire helped the company become a leader in oncology biotech with drugs such as Velcade, with the company eventually being acquired by Takeda.
Prior to her work with Millennium, Ms. Dunshire oversaw the North American oncology business at Novartis, a global health care company based in Switzerland that provides solutions to address the evolving needs of consumers worldwide. Ms. Dunshire now steps in to fill a permanent CEO spot for Lundbeck that has been vacant since last November.
Lundbeck is a global pharmaceutical company engaged in the research and development, production, marking, and sale of drugs for the treatment of disorders in the central nervous system. Some of these disorders include depression, schizophrenia, Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, epilepsy, and insomnia.
This was reported by FierceBiotech on July 6, 2018.
Contact Information: Lundbeck, 6 Parkway North, Deerfield, Illinois, 60015; (866) 337-6996; Website: www.lundbeck.com